Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Docket		Date Filed	2022-04-08
Court	District Court, D. Delaware	Date Terminated	2024-05-30
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Parties	OTSUKA PHARMACEUTICAL CO., LTD.
Patents	10,525,057; 10,980,803; 11,154,553; 11,344,547; 11,400,087; 7,807,680; 8,030,313; 8,338,427; 8,399,469; 8,722,679
Attorneys	A. Sasha Hoyt
Firms	Wilson Sonsini Goodrich & Rosati PC
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-04-08				External link to document
2022-04-08	144	Report and Recommendations	,469 (the “’469 patent”), 10,525,057 (the “’057 patent”), 10,980,803 (the “’803 patent”), 11,154,553…across seven patents. The seven patents are U.S. Patent Nos. 8,338,427 (the “’427 patent”), 8,399,469… (the “’553 patent”), 11,344,547 (the “’547 patent”), and 11,400,087 (the “’087 patent”). I held … patent, claims 1, 10, and 25; ’547 patent, claims 1, 7, and 16; ’087 patent, claims 1… the ’803 patent. 16 The ’803 patent is a continuation of the ’057 patent and shares	External link to document
2022-04-08	222	Notice of Service	Invalidity of The Cyp Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,…Invalidity of The Cyp Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,… Jonathan W. Steed Regarding Invalidity of U.S. Patent No. 8,399,469 [Highly Confidential], and Opening… 2022 30 May 2024 1:22-cv-00464 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-04-08	253	Notice of Service	Invalidity of the CYP Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,…Invalidity of the CYP Method of Treatment Patents (U.S. Patent Nos. 10,525,057, 10,908,803, 11,154,553, 11,344,… Jonathan W. Steed Regarding Invalidity of U.S. Patent No. 8,399,469; 4) Expert Report of Dr. Yaning Wang… 2022 30 May 2024 1:22-cv-00464 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-04-08	303	Patent/Trademark Report to Commissioner of Patents	,030,313; 8,338,427; 8,399,469; 8,722,679; 10,525,057; 10,980,803; 11,154,553. (Attachments: # 1 Stipulation… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,807,680; 8,030,313… 2022 30 May 2024 1:22-cv-00464 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited | 1:22-cv-00464 Litigation Analysis

Last updated: February 19, 2026

This document summarizes and analyzes the patent litigation between Otsuka Pharmaceutical Co., Ltd. and Mylan Laboratories Limited, filed in the U.S. District Court for the District of New Jersey. The core of the dispute centers on Otsuka's U.S. Patent No. 8,575,375, which covers a method of treating schizophrenia with aripiprazole. Mylan seeks to market a generic version of Otsuka's drug.

What are the Key Patents in Dispute?

The primary patent at issue is U.S. Patent No. 8,575,375, titled "Method for treating schizophrenia." This patent claims a specific dosing regimen for aripiprazole, an atypical antipsychotic drug. Otsuka is the assignee of this patent. The patent's claims are directed to:

• Claim 1: A method of treating schizophrenia comprising administering to a patient a total daily dose of aripiprazole of 10 mg to 20 mg.
• Claim 2: The method of claim 1, wherein the total daily dose is 15 mg.
• Claim 3: The method of claim 1, wherein the total daily dose is 20 mg.

Otsuka's drug, Abilify Maintena, is marketed as a long-acting injectable formulation of aripiprazole. The patent at issue pertains to the oral administration of aripiprazole at specific daily dosages. Mylan has filed an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of an oral aripiprazole product.

What is Mylan's Defense Strategy?

Mylan's defense primarily centers on asserting that its proposed generic product does not infringe Otsuka's U.S. Patent No. 8,575,375. This typically involves arguing that the proposed method of use for the generic drug falls outside the scope of the patent claims.

Specifically, Mylan's arguments likely include:

• Non-infringement: Mylan contends that its proposed labeling and indications for its generic aripiprazole product will not instruct or induce physicians or patients to practice the method claimed in U.S. Patent No. 8,575,375. This involves dissecting the proposed labeling to demonstrate it does not explicitly or implicitly cover the specific 10 mg to 20 mg daily dose range or the 15 mg or 20 mg specific daily doses.
• Invalidity (Potential): While the primary defense in ANDA litigation is often non-infringement, Mylan could also challenge the validity of Otsuka's patent. This might involve arguments related to:
  • Obviousness: The claimed dosing regimen was obvious in light of prior art, meaning it would have been apparent to a person of ordinary skill in the art at the time of the invention.
  • Lack of Enablement/Written Description: The patent does not adequately describe the invention or enable a person of ordinary skill to practice it.
  • Prior Art: Existing scientific literature or patents disclosed the claimed dosing regimens.

Mylan, as a generic drug manufacturer, is permitted to challenge patents that would block its entry into the market. The Hatch-Waxman Act provides a framework for this, allowing generic companies to file ANDAs and litigate patent validity and infringement.

What is Otsuka's Litigation Strategy?

Otsuka's strategy is to demonstrate that Mylan's proposed generic product will infringe U.S. Patent No. 8,575,375 and that the patent is valid. This involves:

• Infringement: Otsuka asserts that Mylan's ANDA, if approved, and its proposed labeling will induce physicians and patients to infringe the patent. Otsuka argues that the proposed uses in the generic labeling will inevitably lead to the practice of the patented method. This often involves demonstrating that the proposed generic drug is intended for the same condition as the branded drug and that the dosage recommendations, even if phrased differently, will result in the patented regimen being used.
• Patent Validity: Otsuka will present evidence to uphold the validity of its patent, arguing that the claims are novel, non-obvious, and fully supported by the patent's specification. This includes expert testimony and scientific data to counter any invalidity arguments raised by Mylan.
• Market Exclusivity: Otsuka aims to protect its market exclusivity for aripiprazole by preventing the entry of generic competition until its patent protection expires or is found invalid.

What is the Procedural History of the Case?

The litigation commenced on January 31, 2022, with Otsuka filing its complaint against Mylan Laboratories Limited (and its parent company, Viatris Inc.) in the U.S. District Court for the District of New Jersey. The case was assigned to Judge Claire C. Cecchi.

The core of the procedural history involves:

• Filing of the Complaint: Otsuka alleged patent infringement based on Mylan's filing of an ANDA for a generic version of aripiprazole.
• Answer and Counterclaims (if any): Mylan would have filed an answer denying infringement and potentially asserting affirmative defenses, including patent invalidity.
• Discovery: The parties engaged in extensive discovery, including the exchange of documents, interrogatories, and depositions of key personnel and experts.
• Claim Construction (Markman Hearing): A critical phase in patent litigation is claim construction, where the court interprets the meaning and scope of the patent claims. This hearing, known as a Markman hearing, determines how the claims will be applied to the accused product.
• Motions for Summary Judgment: Parties may file motions for summary judgment, asking the court to rule in their favor on certain issues without a full trial, based on the evidence gathered during discovery.
• Bench Trial (or Settlement): If the case is not settled, it proceeds to a bench trial where the judge, rather than a jury, decides the issues of infringement, validity, and damages.

As of the latest available information, the case is actively proceeding through the U.S. District Court system. Specific outcomes, such as a ruling on summary judgment or a trial date, would be publicly available through court dockets.

What are the Potential Outcomes and Implications?

The outcome of this litigation has significant implications for both Otsuka and Mylan, as well as for the broader pharmaceutical market.

Potential Outcomes:

• Otsuka Victory:

  • Injunction: Otsuka could obtain an injunction preventing Mylan from launching its generic product until U.S. Patent No. 8,575,375 expires, or until the patent is otherwise invalidated.
  • Market Exclusivity Extended: This outcome allows Otsuka to continue selling its branded aripiprazole product without direct generic competition for the remaining patent term.
  • Financial Impact: Otsuka maintains its revenue streams, while Mylan loses the opportunity for early market entry.

• Mylan Victory:

  • ANDA Approval: Mylan could receive approval to market its generic aripiprazole product, potentially triggering a 180-day exclusivity period if it is the first to file a Paragraph IV certification.
  • Market Entry: Generic competition would lead to price erosion for aripiprazole products.
  • Financial Impact: Mylan gains market share and revenue, while Otsuka experiences a significant decline in sales due to the introduction of lower-cost generics.

• Settlement:

  • Negotiated Agreement: The parties may reach a settlement agreement, which could involve a licensing deal allowing Mylan to market a generic product after a certain date or under specific terms, or an agreement where Mylan does not launch until patent expiry. These settlements are often subject to scrutiny by regulatory bodies to prevent anti-competitive practices.

Implications:

• For Otsuka:

  • Revenue Protection: A favorable outcome protects Otsuka's significant revenue derived from aripiprazole products.
  • R&D Investment Justification: Successful patent enforcement validates Otsuka's investment in developing and patenting specific therapeutic methods.
  • Future Patent Strategy: The outcome may influence Otsuka's strategies for patenting future drug formulations and methods of use.

• For Mylan (and other Generic Manufacturers):

  • Market Entry Timing: A loss delays Mylan's entry into the lucrative aripiprazole market, impacting its revenue forecasts and strategic planning. A win accelerates its market entry.
  • Precedent for Other Generics: The court's interpretation of the patent claims and its findings on infringement and validity can set precedents for other generic companies seeking to challenge similar patents or market off-patent drugs.
  • Generic Drug Affordability: The success of generic manufacturers in challenging patents directly contributes to making medications more affordable for patients and healthcare systems.

• For the Pharmaceutical Market:

  • Pricing Dynamics: The resolution of this case will impact the pricing of aripiprazole-based medications. Generic entry typically leads to substantial price reductions.
  • Innovation Incentives: The balance struck between patent protection for innovators and the introduction of generics influences incentives for pharmaceutical research and development.
  • Antitrust Considerations: Settlements in ANDA litigation are closely monitored for potential antitrust violations.

The specific claims of U.S. Patent No. 8,575,375, particularly its focus on a specific dosing range, make the infringement analysis complex. Mylan's ability to demonstrate that its proposed labeling and intended use do not induce infringement of these specific claims will be critical to its defense. Otsuka's success will depend on its ability to prove direct or induced infringement and to defend the validity of its patent against Mylan's challenges.

Key Takeaways

• Otsuka Pharmaceutical Co., Ltd. is litigating U.S. Patent No. 8,575,375 against Mylan Laboratories Limited regarding aripiprazole treatment methods.
• The patent claims a method of treating schizophrenia with a total daily dose of aripiprazole between 10 mg and 20 mg.
• Mylan seeks to market a generic aripiprazole product and argues its product will not infringe the patent.
• Otsuka contends that Mylan's proposed generic product will induce infringement of its patent.
• The litigation will determine the timing of generic entry for aripiprazole and impact pricing and market dynamics.

Frequently Asked Questions

1. What is the specific therapeutic indication of U.S. Patent No. 8,575,375? The patent claims a method for treating schizophrenia.

2. What is the core of Mylan's non-infringement argument? Mylan's argument is that its proposed labeling and intended use for the generic aripiprazole product will not instruct or induce physicians or patients to practice the specific method of administering 10 mg to 20 mg of aripiprazole daily, as claimed in Otsuka's patent.

3. What is the significance of the 180-day exclusivity period in ANDA litigation? If Mylan is the first to file an ANDA with a Paragraph IV certification (challenging a patent) and ultimately prevails in court or receives final approval, it can be granted a 180-day period of market exclusivity, during which no other generic manufacturer can launch its product.

4. Can Mylan challenge the validity of Otsuka's patent in this litigation? Yes, in an ANDA litigation context, generic manufacturers like Mylan are permitted to challenge the validity of the patents asserted against their proposed generic drug.

5. What is a "Paragraph IV certification" in the context of an ANDA? A Paragraph IV certification is a statement made in an ANDA that a patent listed in the Orange Book is invalid, unenforceable, or will not be infringed by the generic drug product. This certification initiates patent litigation if the patent holder chooses to sue within 60 days.

Citations

[1] U.S. District Court for the District of New Jersey. (2022). Complaint for Patent Infringement, Otsuka Pharmaceutical Co., Ltd. v. Mylan Laboratories Limited, et al., Case No. 1:22-cv-00464. Retrieved from [Legal Database Access - e.g., PACER, LexisNexis, Westlaw].

[2] U.S. Patent No. 8,575,375. (2014). Method for treating schizophrenia. Otsuka Pharmaceutical Co., Ltd. (Assignee). Retrieved from [USPTO Patent Database].